Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Nurix Therapeutics (NRIX) Enterprise Value: 2019-2025

Historic Enterprise Value for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $285.2 million.

  • Nurix Therapeutics' Enterprise Value fell 75.73% to $285.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$1.4 billion, marking a year-over-year decrease of 779.62%. This contributed to the annual value of $956.6 million for FY2024, which is 6839.26% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Enterprise Value of $285.2 million as of Q3 2025, which was down 12.14% from $324.6 million recorded in Q2 2025.
  • Nurix Therapeutics' Enterprise Value's 5-year high stood at $1.2 billion during Q3 2024, with a 5-year trough of $13.8 million in Q4 2023.
  • For the 3-year period, Nurix Therapeutics' Enterprise Value averaged around $475.7 million, with its median value being $324.6 million (2025).
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 93.78% in 2023, then surged by 6,839.26% in 2024.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Enterprise Value stood at $990.0 million in 2021, then plummeted by 77.60% to $221.7 million in 2022, then tumbled by 93.78% to $13.8 million in 2023, then spiked by 6,839.26% to $956.6 million in 2024, then crashed by 75.73% to $285.2 million in 2025.
  • Its Enterprise Value stands at $285.2 million for Q3 2025, versus $324.6 million for Q2 2025 and $622.8 million for Q1 2025.